LIVE
LLY
Eli Lilly and Company · Healthcare
$1,208.12
+11.56% this month
VERSUS
⟷
COMPARE
ABBV
AbbVie Inc. · Healthcare
$253.35
+17.62% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
LLY
3
ABBV
2
Comparison scoreboard
LLY LEADS 3/5AI Score
LLY ✓73.1
ABBV 51.3
1Y Return
LLY ✓+52.48%
ABBV +36.66%
Fwd P/E
LLY 24.71
ABBV ✓13.32
Target Up.
LLY +10.94%
ABBV ✓+17.12%
Op. Margin
LLY ✓49.39%
ABBV 32.16%
Metrics last refreshed: 6/28/2026
Quick take
LLY vs ABBV: Eli Lilly vs AbbVie Stock Comparison: AI Score, Valuation, Performance and Upside
Eli Lilly is the GLP-1 growth juggernaut with the fastest-growing drug franchise in pharma history and massive obesity market expansion potential. AbbVie is a diversified pharma company navigating the Humira-to-Skyrizi/Rinvoq transition with a high dividend yield and broader therapeutic area exposure. Lilly has superior growth; AbbVie has better income and diversification.
Use this LLY vs ABBV comparison to evaluate two pharma investment approaches. Eli Lilly offers concentrated GLP-1/obesity growth at a premium valuation; AbbVie offers diversified pharma income with strong immunology growth at a more moderate valuation.
Live analysis · updated 6/28/2026
LLY holds the edge across 3 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+52.48% vs +36.66%), though ABBV trades at the lower forward P/E (13.32x vs 24.71x). LLY leads on both revenue growth (55.50%) and operating margin (49.39%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+17.12%) than for LLY (+10.94%).
Normalized 1Y performance
LLY
ABBV
Recent returns
LLY
ABBV
Analyst price targets & sentiment
LLY · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$650.00
analyst mean$1,218.72
current price$1,208.12
+10.9% upside to analyst mean
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$253.35
+17.1% upside to analyst mean
Who should consider this stock?
LLY may suit investors who:
- →Want exposure to the GLP-1/obesity megatrend through the market-leading tirzepatide franchise
- →Believe the obesity drug market TAM is large enough to justify Eli Lilly's premium valuation
- →Value Lilly's pipeline optionality in Alzheimer's, oncology, and next-generation oral GLP-1 formulations
- →Are comfortable with a growth-stock valuation for a pharmaceutical company
ABBV may suit investors who:
- →Prefer a diversified pharma company with exposure across immunology, aesthetics, neuroscience, and oncology
- →Value AbbVie's high dividend yield and Dividend Aristocrat status for income-oriented portfolios
- →Believe Skyrizi and Rinvoq can fully replace and exceed Humira revenue over the next several years
- →Want pharma exposure at a more moderate valuation with better near-term income generation
Performance & AI score
| Metric | LLY | ABBV |
|---|---|---|
| AI score | 73.1 | 51.3 |
| AI rank | #24 | #345 |
| Latest close | $1,208.12 | $253.35 |
| 1M return | +11.56% | +17.62% |
| 6M return | +12.18% | +10.20% |
| 1Y return | +52.48% | +36.66% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | ABBV |
|---|---|---|
| 1Y ago | $15.19K (+51.9%) started 2025-06-26 | $13.56K (+35.6%) started 2025-06-26 |
| 5Y ago | $57.4K (+474.0%) started 2021-06-28 | $30.98K (+209.8%) started 2021-06-28 |
| 10Y ago | $222.34K (+2123.4%) started 2016-06-27 | $99.97K (+899.7%) started 2016-06-27 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | LLY | ABBV |
|---|---|---|
| Market cap | $979.64B | $382.49B |
| Trailing P/E | 39.07 | 106.12 |
| Forward P/E | 24.71 | 13.32 |
| Price/Sales | 14.10 | 5.85 |
| EV/Revenue | 14.09 | 7.10 |
| Analyst target | $1,218.72 | $253.55 |
| Target upside | +10.94% | +17.12% |
Growth, profitability & risk
| Metric | LLY | ABBV |
|---|---|---|
| Revenue growth | 55.50% | 12.40% |
| Earnings growth | 169.90% | -46.20% |
| EPS growth | +169.90% | -46.20% |
| FCF margin | +12.67% | +33.13% |
| Operating margin | 49.39% | 32.16% |
| Profit margin | 34.99% | 5.79% |
| ROIC proxy | 107.46% | 6225.00% |
| Return on equity | 107.46% | 6225.00% |
| Dividend yield | 0.63% | 3.20% |
| Beta | 0.52 | 0.31 |
| Debt/equity | 139.01 | 4789.60 |
| Current ratio | 1.50 | 0.80 |
| Quick ratio | 0.72 | 0.52 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
LLY max drawdown23.31%
ABBV max drawdown19.23%
LLY max wkly drop17.93%
ABBV max wkly drop8.49%
5Y risk snapshot
LLY max drawdown34.48%
ABBV max drawdown21.92%
LLY max wkly drop17.93%
ABBV max wkly drop17.30%
10Y risk snapshot
LLY max drawdown34.48%
ABBV max drawdown45.09%
LLY max wkly drop17.93%
ABBV max wkly drop19.39%
Performance metrics by period
| Period | Metric | LLY | ABBV |
|---|---|---|---|
| 1Y | Growth | +51.94% | +35.63% |
| CAGR | +52.03% | +35.69% | |
| Sharpe ratio | 1.17 | 1.14 | |
| Max drawdown | 23.31% | 19.23% | |
| Max daily drop | 14.14% | 5.20% | |
| Max wkly drop | 17.93% | 8.49% | |
| 5Y | Growth | +451.04% | +161.91% |
| CAGR | +40.73% | +21.26% | |
| Sharpe ratio | 1.08 | 0.76 | |
| Max drawdown | 34.48% | 21.92% | |
| Max daily drop | 14.14% | 12.57% | |
| Max wkly drop | 17.93% | 17.30% | |
| 10Y | Growth | +1782.49% | +531.36% |
| CAGR | +34.13% | +20.24% | |
| Sharpe ratio | 0.97 | 0.67 | |
| Max drawdown | 34.48% | 45.09% | |
| Max daily drop | 14.14% | 16.25% | |
| Max wkly drop | 17.93% | 19.39% |
Business comparison
| Category | LLY | ABBV |
|---|---|---|
| Company | Eli Lilly and Company | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Global pharmaceutical company leading the GLP-1 revolution with Mounjaro (tirzepatide) for diabetes and Zepbound for obesity. Also developing treatments in Alzheimer's, oncology, and immunology. | Global biopharmaceutical company with leading positions in immunology (Skyrizi, Rinvoq), aesthetics (Botox, Juvederm), neuroscience, oncology, and eye care. Navigating the Humira biosimilar transition. |
| Investor focus | Mounjaro/Zepbound prescription growth, manufacturing capacity expansion, obesity market penetration, Alzheimer's drug (donanemab) commercial launch, and pipeline depth. | Skyrizi and Rinvoq growth trajectory post-Humira, aesthetics recovery, neuroscience pipeline, dividend sustainability, and revenue diversification beyond immunology. |
LLY strengths
- →Market-leading GLP-1 franchise — Mounjaro and Zepbound are the fastest-growing drug brands in pharma history
- →Obesity represents a massive TAM expansion — tens of millions of potential patients beyond the diabetes population
- →Strong pipeline with donanemab (Alzheimer's), oncology assets, and next-generation oral GLP-1 formulations
ABBV strengths
- →Skyrizi and Rinvoq are successfully replacing Humira revenue with combined peak sales potentially exceeding Humira's peak
- →Diversified revenue across immunology, aesthetics (Allergan), neuroscience, and oncology provides stability
- →Strong dividend with high yield — AbbVie is a Dividend Aristocrat with a commitment to growing its payout
Risks to watch — LLY
- →Premium valuation (highest P/E among large-cap pharma) requires sustained GLP-1 demand and supply execution
- →Manufacturing capacity constraints for tirzepatide — scaling production to meet demand is a multi-year challenge
- →GLP-1 competition from Novo Nordisk (semaglutide) and emerging oral GLP-1 players could pressure market share
Risks to watch — ABBV
- →Humira biosimilar erosion continues — Skyrizi and Rinvoq must grow fast enough to offset the decline
- →Aesthetics market (Botox, Juvederm) has been softer than expected due to consumer spending headwinds
- →Patent cliffs on key drugs create ongoing need for pipeline replenishment through R&D and M&A
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →